|Joint Book-Running Managers:
Citigroup Global Markets Inc.
Goldman Sachs & Co. LLC
Barclays Capital Inc.
Morgan Stanley & Co. LLC
BofA Securities, Inc.
J.P. Morgan Securities LLC
HSBC Securities (USA) Inc.
Mizuho Securities USA LLC
BNP Paribas Securities Corp.
Credit Suisse Securities (USA) LLC
Deutsche Bank Securities Inc.
MUFG Securities Americas Inc.
RBC Capital Markets, LLC
Sumitomo Mitsui Financial Group, Inc.
Wells Fargo Securities, LLC
Samuel A. Ramirez & Company, Inc.
Changes to Preliminary Prospectus Supplement
The second paragraph of the section entitled “Use of Proceeds”
is revised in its entirety to read as set forth below. (Additional
conforming changes will be made to the Preliminary Prospectus
Supplement consistent with these changes.)
“We intend to use the net proceeds from this offering to
(i) redeem in full our outstanding 3.45% Senior Notes due 2020
in an aggregate outstanding principal amount of $900 million,
which have a stated maturity date of October 1, 2020, (ii)
redeem in full our 4.10% Senior Notes due 2021 in an aggregate
outstanding principal amount of $1.0 billion, which have a
stated maturity date of June 15, 2021, (iii) redeem in full
our 1.85% Senior Notes due 2021 in an aggregate outstanding
principal amount of $750 million, which have a stated maturity
date of August 19, 2021 and (iv) redeem $300 million
aggregate principal amount of our 3.875% Senior Notes due 2021 (of
which $1.75 billion aggregate principal amount of such Notes
is currently outstanding), which have a stated maturity date of
November 15, 2021. The redemption of each series of notes will
include the payment of a make-whole amount and accrued and unpaid
interest on the notes to, but not including, the date of
redemption. We intend to use any remaining net proceeds from this
offering to repay our outstanding indebtedness and for general
Amgen Inc. has filed a registration statement (including a
prospectus dated as of February 10, 2020) and a prospectus
supplement dated as of February 18, 2020 with the SEC for the
offering to which this communication relates. Before you invest,
you should read the prospectus in that registration statement, the
prospectus supplement and other documents Amgen Inc. has filed with
the SEC for more complete information about the issuer and this
offering. You should rely on the prospectus, prospectus supplement
and any relevant free writing prospectus or term sheet for complete
details. You may get these documents for free by visiting the SEC
web site at www.sec.gov. Alternatively, copies of the prospectus
and the prospectus supplement may be obtained from
(i) Citigroup Global Markets Inc. toll-free at 1-800-831-9146, (ii)
Goldman Sachs & Co. LLC. toll-free at 1-866-471-2526, (iii)
Barclays Capital Inc. toll-free at 1-888-603-5847 and
(iv) Morgan Stanley & Co. LLC toll-free at
The security ratings above are not a recommendation to
buy, sell or hold the securities offered hereby. The ratings may be
subject to revision or withdrawal at any time by Moody’s and
S&P. Each of the security ratings above should be evaluated
independently of any other security rating.
Any disclaimer or other notice that may appear below is not
applicable to this communication and should be disregarded (other
than any statement relating to the identity of the legal entity
authorizing or sending this communication in a non-US jurisdiction). Such disclaimer
or notice was automatically generated as a result of this
communication being sent by Bloomberg or another e-mail system.